Psychedelics have specific drug actions, such as inducing structural and functional neural plasticity, that could potentially treat mental health conditions and impact diseases affecting the brain,...
Return Health is exploring psychedelic derivatives for the treatment of dementia.
The acquisition includes all future worldwide rights relating to the use of psychedelics to treat Alzheimer’s disease and other dementias.
With limited treatment options available for the condition, one company is setting out to explore the neurogenic potential of psychedelics to combat the cognitive decline of...
Currently, there is no cure for Parkinson’s Disease, however, certain medications can help improve symtoms.
Delix Therapeutics has raised $70m in a Series A funding round which is expected to fund its drug discovery platform of novel neuroplasticity-promoting compounds known as...
